Comparing BTK inhibitors in relapsed/refractory CLL; unraveling the genetic background of the AnWj-negative blood type; rapid adaptation of CLL cells to venetoclax
This episode discusses BTK inhibitors for relapsed/refractory CLL, the genetic basis of the rare AnWj blood type, and how CLL cells adapt to venetoclax therapy through the BAFF/BCL-2 pathway.